Cabergoline is a peptide that acts as a dopamine receptor agonist on D2 receptors. It is occasionally referred to by the name Dostinex. It is typically presented in the form of white powder and is insoluble in water.
Mechanics of Cabergoline
According to scientific study that has been conducted on animal test subjects, Cabergoline functions as a long-acting agonist that displays a direct inhibitory effect on the prolactin secretion in the lactotroph cells found in the pituitary gland. Although primarily associated with its role in lactation, prolactin has several other forms of functionality within animal test subjects. The secretion has been linked to the regulation of an organism’s immune system, the formation of blood cellular components, blood clotting regulation, and angiogenesis.
The introduction of the cabergoline peptide is to inhibit the production of prolactin within animal test subjects. Scientific study has determined the peptide can counterbalance an excessive production of prolactin in animal test subjects; a condition that may be caused by a condition stemming from prolactinoma, which is a benign tumor of the pituitary gland that could cause an excess amount of prolactin production.
Theoretical Benefits of Cabergoline
Scientific study based on animal test subjects in relation to Cabergoline has determined several theoretical benefits associated with the peptide.
The primary theoretical benefit is to potentially counteract the effects that could be brought upon the presence of prolactinoma in the pituitary gland; a tumor-based condition that causes an excessive amount of prolactin to be secreted. Although the tumor is benign, the presence of a prolactinoma – and the subsequent excessive production of prolactin – can cause several issues within the body of an animal test subject. Some of the issues linked to prolactinoma include:
- Amenorrhea – This refers to the absence of a menstrual period amongst female animal test subjects that are of reproductive age.
- Galactorrhea – This refers to the spontaneous flow of breast mile that is unassociated with nursing. Although this condition has been primarily linked to female animal test subjects, infrequent cases of this condition occurring amongst male animal test subjects have also been recorded through scientific study.
- Hypogonadism – This refers to diminished functionality of the testes in male animal test subjects, and the ovaries in female test subjects.
- Gynecomastia – This refers to the benign enlargement of breast tissue in male animal test subjects.
It is theorized through scientific study on animal test subjects that the introduction of the peptide and its ability to inhibit the production of prolactin could stem these effects that are associated with prolactinoma.
Other theoretical benefits associated with cabergoline based on scientific study on animal test subjects include a slowing of the aging process as well as an increased efficiency in the growth of muscular and skeletal tissue.
Potential Negative Side Effects of Cabergoline
Even though there have been several positive theoretical benefits associated with Cabergoline which have been determined through scientific study on animal test subjects, there have also been several negative side effects that have been linked to the peptide through this kind of research. Serious potential negative side effects associated with Cabergoline include:
- Difficulty in breathing
- Light-headedness
- Fainting
- Hallucinations
Less serious potential side effects that have been linked to Cabergoline include:
- Nausea
- Stomach pain
- Constipation
- Headache
- Vomiting
- Dizziness or Vertigo
- Drowsiness
- Numbness
- Excessive tingling
- Itchiness
- Bloating of extremities
- Rapid weight gain
- General feeling of discomfort
- Swelling around eyes
Additionally, scientific study on animal test subjects has theorized other potential negative side effects can be associated with Cabergoline. These theoretical side effects range from mild effects such as loss of appetite and weakness to more severe effects such as the tightening of the chest or continuous vomiting. However, there has yet to be sufficient research conducted to determine the frequency of the manifestations of these particular negative side effects.
For Scientific Use Only
Although there has been numerous scientific studies conducted on animal test subjects in order to determine Cabergoline’s range of operational mechanics, theoretical benefits, and negative side effects, it should be noted that any and all findings that are associated with the peptide are still considered to be the product of current laboratory research investigation. Because Cabergoline is currently in the research phase, any study or usage in relation to the mechanics, operations, effects, benefits, and side effects of the peptide should exclusively be contained to the restrictions of a strictly controlled environment such as a laboratory or a medical research facility.





